What's Happening?
Sustained Therapeutics, a clinical-stage urologic therapeutics company, has announced positive results from its Phase 2 study of ST-01, a non-opioid sustained-release small molecule therapy for men with chronic scrotal content pain (CSCP). The data was
presented at the American Urological Association 2026 Annual Meeting in Washington, DC. The study demonstrated that ST-01, at a 70 mg/mL dose, significantly improved pain reduction and clinical response rates compared to the standard of care. The treatment was well tolerated, with durable responses over repeated dosing cycles. The study involved 63 men across eight clinical sites in Canada, showing that 67% of patients treated with ST-01 achieved a significant reduction in pain scores, compared to 26% in the control group.
Why It's Important?
The findings from this study are significant as they offer a potential new treatment option for chronic scrotal content pain, a condition affecting an estimated 5 million men in North America. Current treatments are limited and often involve opioids or invasive surgery, which can have significant side effects and risks. ST-01's non-opioid profile and targeted delivery could provide a safer, more effective alternative, potentially transforming care for patients and reducing healthcare costs associated with chronic pain management. The success of ST-01 could also pave the way for its application in other chronic pain conditions, such as chronic pelvic pain, further expanding its impact.
What's Next?
Sustained Therapeutics plans to advance ST-01 to Phase 3 development, pending regulatory review. The company is also exploring the broader applicability of its sustained-release platform for other chronic pain indications. The positive reception of ST-01 within the urology community suggests a strong demand for non-opioid pain management solutions, which could drive further research and development in this area. The company aims to continue its efforts to provide innovative, non-surgical treatment options for chronic urologic pain, potentially improving patient outcomes and quality of life.
